在中国,HutchMED 第三阶段试验测试四组药物作为先进的胰腺癌的一线治疗,将其与标准疗法作比较。 HutchMED launches Phase III trial in China testing a four-drug combo as first-line treatment for advanced pancreatic cancer, comparing it to standard therapy.

HUTCHMED已经开始在中国进行三期试验,试验四种药物组合苏法提尼布,卡梅利祖马布,纳布-帕克利塔塞尔和吉姆奇塔宾作为转移性胰腺管腺癌的第一线治疗. HUTCHMED has started the Phase III stage of a trial testing a four-drug combination—surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine—as a first-line treatment for metastatic pancreatic ductal adenocarcinoma in China. 审判于2025年12月开始,开始收治病人,计划收治约400名治疗性慢性病人,并将综合疗法与标准nab-paclitaxel和Guncitabine疗法作比较。 The trial, which began enrolling patients in December 2025, plans to include about 400 treatment-naïve patients and compares the combination to standard nab-paclitaxel and gemcitabine therapy. 首要目标是全面生存,有次级终点,包括无进展生存和安全。 The primary goal is overall survival, with secondary endpoints including progression-free survival and safety. 第二阶段早期的结果显示,尽管总体生存数据仍然不成熟,但无进步生存和响应率有所改善。 Earlier Phase II results showed improved progression-free survival and response rates, though overall survival data remain immature. 尽管副作用更为严重,但组合具有可管理的安全特征。 The combination had a manageable safety profile despite more severe side effects. 试验是公开标签和多中心试验,其结果预计将为这种攻击性癌症的未来治疗标准提供参考。 The trial is open-label and multicenter, with results expected to inform future treatment standards for this aggressive cancer.